ETRIPAMIL
On-Demand Intranasal Therapy for PSVT
(Guideline-Directed Overview)
WHAT IS ETRIPAMIL
• Intranasal, ultra-short-acting AV-nodal calcium channel blocker
• FDA-approved for on-demand termination of paroxysmal supraventricular tachycardia (PSVT)
ROUTE & PHARMACOKINETICS
• Route: Nasal spray (self-administered)
• Onset: 2–5 minutes
• Duration: ~20–30 minutes
MECHANISM OF ACTION
• Transient AV-nodal calcium channel blockade
• Interrupts re-entry circuit
• Terminates AVNRT and AVRT
GUIDELINE-DIRECTED ROLE
• Hemodynamically stable PSVT
• Recurrent, self-terminating episodes
• Suitable for out-of-hospital use
• Alternative to IV adenosine when access is limited
• Aligns with ACC/AHA/HRS SVT management principles (acute AV-nodal blockade)
KEY ADVANTAGES
• No IV access required
• No adenosine-like chest discomfort or flushing
• Rapid symptom relief
• Potential reduction in emergency department visits
ADVERSE EFFECTS
• Mild nasal irritation or congestion
• Transient bradycardia
• Transient hypotension
NOT INDICATED FOR
• Atrial fibrillation
• Atrial flutter
• Hemodynamically unstable tachycardia
CLINICAL IMPACT
• Empowers patient-initiated therapy
• Improves quality of life in recurrent PSVT
• Shifts care from ER-based to home-based management
For more cardiology infographics
drmusmanjaved.com

Comments
Post a Comment
Drop your thoughts here, we would love to hear from you